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Endovascular Stenting for Vertebral Artery Stenosis
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Objectives The aim of this study was to demonstrate the safety and long-term durability of catheter-based therapy for
symptomatic vertebral artery stenosis (VAS).
Background Symptomatic VAS carries with it a 5-year 30% to 35% risk of stroke. The 2-year mortality approaches 30% for
medically managed strokes involving the posterior circulation. Surgical bypass is rarely performed, due to high
morbidity and mortality. Endovascular revascularization with primary stenting offers an attractive treatment op-
tion for these patients.
Methods One-hundred five consecutive symptomatic patients (112 arteries, 71% male) underwent stent placement for
extracranial (91%) and intracranial (9%) VAS from 1995 to 2006. Fifty-seven patients (54%) had bilateral VAS,
71 patients (68%) had concomitant carotid disease, and 43 patients (41%) had a prior stroke.
Results Procedural and clinical success was achieved in 105 (100%) and 95 (90.5%) patients, respectively. One-year
follow-up was obtained in 87 (82.9%) patients, of which 69 patients (79.3%) remained symptom-free. At 1 year,
6 patients (5.7%) had died and 5 patients (5%) had a posterior circulation stroke. Target vessel revascularization
occurred in 7.4% at 1 year. At a median follow-up of 29.1 months (interquartile range 12.8 to 50.9 months),
13.1% underwent target vessel revascularization, 71.4% were alive, and 70.5% remained symptom-free.
Conclusions In experienced hands, stenting for symptomatic VAS can be accomplished with a very high success rate (100%),
with few periprocedural complications, and is associated with durable symptom resolution in the majority (ap-
proximately 80%) of patients. We conclude that endovascular stenting of vertebral artery atherosclerotic disease
is safe and effective compared with surgical controls and should be considered first-line therapy for this
disease. (J Am Coll Cardiol 2010;55:538–42) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.069J
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approximately 80% of strokes are ischemic in origin, of
hich 20% to 25% are located in the posterior circulation
nvolving the vertebrobasilar system (VBS) (1–3). The
rognosis for patients with atherosclerotic occlusion or
hrombosis of the VBS is poor, with 80% to 100% mortality
4). Medically refractory, symptomatic VBS disease carries a
% to 11% incidence of stroke or death at 1 year (5–8).
ransient ischemic attacks (TIA) due to extracranial VBS
isease are associated with a stroke rate of 30% at 5 years
8–10).
Although the incidence in the general population of
ertebral artery stenosis (VAS) is unknown, patients with
therosclerotic peripheral arterial disease (PAD) have a 40%
ncidence of VAS (11). Patients with symptomatic VBS
schemia have a 25% to 40% incidence of VAS (12). The
rom the John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation,
ew Orleans, Louisiana. Dr. White is a principal investigator in the CABANA trial
Boson Scientific), and is on the advisory board of Baxter Cellular Therapy. Dr.
amee is an investor/cofounder of SquareOne, Inc.s
Manuscript received April 17, 2009; revised manuscript received August 7, 2009,
ccepted August 10, 2009.oint Study of Extracranial Arterial Occlusion examined
,800 patients who presented for angiography due to symp-
omatic cerebrovascular disease and found a 40% incidence
f VAS and a 10% incidence of complete occlusion of 1
ertebral artery (13).
Although VAS is highly prevalent in patients with PAD,
ts association with symptoms of vertebrobasilar insuffi-
iency (VBI) is both under-recognized and underdiagnosed
14). Symptoms associated with VBI, such as dizziness,
taxia, visual disturbances, and motor-sensory deficits,
ight be dismissed as nonspecific findings. Noninvasive
maging of the ostial and proximal vertebral artery, the most
requent site of vertebral atherosclerotic obstructive disease
s difficult and often incomplete (15). Although initial
ntithrombotic and antiplatelet therapy is warranted, arch
nd 4-vessel angiography, computed tomographic angiog-
aphy, or magnetic resonance angiography is indicated if
ymptoms continue despite maximal medical therapy (13).
Three surgical revascularization techniques for symptom-
tic vertebral disease have been described. These open
urgical procedures include: 1) transection of the vertebral
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February 9, 2010:538–42 Vertebral Artery Interventionrtery above the stenosis with reimplantation into the
psilateral subclavian or carotid artery; 2) vertebral artery
ndarterectomy; and 3) vein patch angioplasty. The com-
ined morbidity and mortality rates of VAS surgical therapy
ange from 10% to 20% and have dampened enthusiasm for
his option (10,16–19).
Management of VAS has shifted to percutaneous
echniques with the evolution of endovascular device
echnologies. Sundt et al. (20) reported the first vertebral
rtery intraoperative transluminal angioplasty in 1980. Since
hen, multiple case reports and clinical series have described
he use of balloon angioplasty and stenting to treat verte-
robasilar atherosclerotic disease (15,21–29). In this article,
e report acute and long-term outcomes in 105 consecutive
ymptomatic patients (112 arteries) undergoing endovascu-
ar stenting of VAS over an 11-year period.
ethods
atient population. Between December 1995 and May
006, 105 consecutive symptomatic patients (112 arteries)
nderwent endovascular stenting of extracranial (91%) and
ntracranial (9%) atherosclerotic vertebral artery disease
Tables 1 and 2). The population was predominantly male
71%) with mean age of 67.8  11 years (range 43 to 94
ears). Patients were diagnosed with VAS by clinical assess-
ent coupled with imaging techniques. The diagnosis was
onfirmed by independent neurological evaluation by a
ember of the stroke team not participating in the inter-
ention. All patients had failed management with antiplate-
et therapy. Symptoms included vertigo, visual changes,
yncope, ataxia, drop attack, or stroke/TIA (Table 1).
atient CharacteristicsTable 1 Patient Characteristics
Patients (n  105)
Age (yrs) 67.8 11
Male 74 (70.5)
Indication for procedure
Vertigo 69 (65.7)
Visual disturbance 34 (32.4)
Syncope 12 (11.4)
CVA/TIA 9 (8.6)
Ataxia 8 (7.6)
Drop attack 5 (4.8)
Comorbidities
Coronary artery disease 69 (65.7)
Hypertension 89 (86.4)
Diabetes 29 (28.4)
Hyperlipidemia 83 (83.0)
History of tobacco use 51 (52.6)
Concurrent carotid disease 71 (68.9)
Concurrent subclavian disease 26 (29.2)
Bilateral vertebral disease 57 (54.3)
Prior CVA 43 (41.0)M
alues are mean  SD or n (%).
CVA  cerebrovascular accident; TIA  transient ischemic attack.esion characteristics. One
undred five arteries were treated
ith stents (Table 2). Seven
6.7%) patients underwent treat-
ent of both vertebral arteries.
ngiographic evaluation. Aor-
ic arch and 4-vessel angiogra-
hy, including carotid and verte-
ral artery angiography, was
erformed in all patients. Intra-
ranial imaging to define the an-
erior circulation, posterior circu-
ation, and the circle of Willis
as included in all studies.
echnique. All patients received aspirin (325 mg once
aily) and ticlodipine (250 mg twice daily) or clopidogrel
75 mg once daily) before the procedure. All patients
eceived 5,000 to 10,000 U of heparin after arterial access to
aintain an activated clotting time 250 s.
Selective engagement of the vertebral artery was per-
ormed with an appropriate-shaped 6-F coronary guiding
atheter. A 0.014-inch steerable coronary guidewire was
dvanced across the stenosis, and no embolic protection
evices were used in this series of patients. The reference
essel diameter was determined with quantitative angiogra-
hy before balloon angioplasty and stent placement
Table 2). After stent deployment, completion angiography
as performed.
Minimal or no sedation was used during the procedure,
nd continuous neurological monitoring was performed.
ost-procedure antiplatelet therapy included dual antiplate-
et therapy (aspirin and thienopyridines) for a minimum of
month and continued at the treating physicians’
iscretion.
efinitions. Technical success was defined as residual
tenosis 30% without in-hospital stroke or death. Clinical
uccess was defined as technical success with VBS symptom
esolution. Target vessel revascularization was defined as
epeat intervention of the target vessel driven by clinical
ymptoms with a 70% stenosis. Major complications
ncluded death and stroke.
ollow-up. Outpatient clinic visits were encouraged at
egular intervals, and symptom status was assessed. Nonin-
asive imaging with duplex ultrasound was at the physician’s
iscretion and was often performed in conjunction with
utpatient clinic visits. Repeat angiography was performed
f repeat revascularization was being considered for recur-
ent symptoms with suspicion of restenosis on noninvasive
maging. The incidence of mortality and the date of death
ere determined via the Social Security Death Index.
tatistical analysis. Categorical data were presented as
ercentages, and continuous variables were presented as
ean SD. Survival rates were calculated with the Kaplan-
Abbreviations
and Acronyms
PAD  peripheral arterial
disease
TIA  transient ischemic
attack
VAS  vertebral artery
stenosis
VBI  vertebrobasilar
insufficiency
VBS  vertebrobasilar
systemeier Product Limit method.
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rocedural outcome. Technical success was achieved in all
12 arteries (100%) (Table 3). There was 1 VBS stroke that
eveloped within the first month after the procedure.
linical success was achieved in 95 (90.5%) of 105 symp-
omatic patients (Table 3). Of the 10 patients who did not
chieve clinical success, 1 developed a VBS stroke 3 days
fter hospital discharge and 9 had persistent symptoms.
eriprocedural complications before hospital discharge oc-
urred in 5 (4.8%) patients (Table 4).
ollow-up. Of a total of 105 patients (112 arteries), 5
atients (5 arteries) were lost to follow-up. Clinical
ollow-up was obtained in 100 (95.2%) patients (107 arter-
es) at a median of 29.1 months (interquartile range 12.8 to
0.9 months), with 87 (82.9%) patients (94 arteries) having
t least 1-year follow-up. At 1 year, 6 patients (5.7%) had
ied, and 5 patients (4.8%) experienced a VBS stroke.
arget vessel revascularization occurred in 13.1% (14 of 107
rteries) at 29.1 months (Table 3).
urvival. Although there were no in-hospital deaths, there
as 1 patient death within 30 days of the procedure
econdary to a myocardial infarction. At the median
rocedural DataTable 2 Procedural Data
Artery treated (n  112)
Left vertebral 63 (56.3)
Right vertebral 49 (43.7)
Bilateral 7 (6.3)
Segment treated (n  117)
V1 97 (82.9)
V2 7 (6.0)
V3 2 (1.7)
V4 11 (9.4)
Stent type (n  133)
Balloon-expandable bare-metal 114
Self-expanding 16
Balloon-expandable drug-eluting 3
Stent diameter 4.1 0.7
Stent length 13.4 6.4
Stenosis (%)*
Pre-intervention 89.2 9.1
Post-intervention 1.4 4.8
alues are n (%) or mean  SD. *Angiographic visual estimation.
linical End Points and Long-Term Follow-UpTable 3 Clinical End Points and Long-Term Follow-Up
Technical success (n  112) 112 (100)
Clinical success (n  105) 96 (91.4)
Clinical follow-up (n  105)
All patients 100 (95.2)
Median, months 29.1 [12.8–50.9]
Patients with 1-yr follow-up 87 (82.9)
Asymptomatic at last follow-up (n  100) 74 (74.0)
Target vessel revascularization
All vessels (n  107)* 14 (13.1)alues are n (%) or median [interquartile range]. *Excludes 5 vessels lost to follow-up.ollow-up of 29.1 months, 71.4% of all treated patients were
live. The overall patient survival is shown in Figure 1.
iscussion
n experienced hands, catheter-based treatment with stents
or symptomatic VAS can be successfully accomplished in a
ery high percentage (100%) of patients, with rare major
omplications (no in-hospital strokes or deaths). Stenting of
AS provides durable symptom resolution in approximately
0% of patients at 2.5 years of follow-up.
Although medical therapy for the management of VBS
schemia traditionally includes warfarin anticoagulation or
ntiplatelet therapy, there is lack of evidence supporting the
se of these drugs for this disease or comparing these drugs
o other treatment options (17,30–32). Surgical options
emain unattractive, due to the difficulty in gaining access to
he origin of the vertebral artery and the increased morbidity
nd mortality (33).
There has been only 1 very small prospective randomized
rial that compared VAS stent placement with medical
herapy (CAVATAS [Carotid and Vertebral Artery Trans-
uminal Angioplasty Study], n  16) (33). Eight patients
ere randomized to medical therapy, and 8 patients under-
Figure 1 Overall Survival
With the Kaplan-Meier Product Limit method, median survival is 10.1 years
(121 months) with August 15, 2007, as the censoring date. Of 105 patients,
72.5% were censored and 30 (28.6%) died.
rocedural Complications (n  105)Table 4 Procedural Complications (n  105)
Stroke 0 (0)
Transient ischemic attack 1 (1.0)
Dissection (flow-limiting) 1 (1.0)
Hematoma/bleeding requiring transfusion 2 (1.9)
Access site complications 1 (1.0)
All complications 5 (4.8)
alues are n (%).
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February 9, 2010:538–42 Vertebral Artery Interventionent successful endovascular stenting, with no strokes or
eath occurring within 30 days in either group. At mean
ollow-up of 4.7 years, there were no vertebral strokes in
ither group.
A Cochrane Review identified 173 cases of VAS
tenting of 313 cases of vertebral artery intervention (34).
nalysis of these 20 studies found a 30-day major stroke
nd death rate of 3.2% and a 30-day TIA and nondis-
bling stroke rate of 3.2%. This meta-analysis suggests
hat vertebral artery stenting is safe and effective, al-
hough a selection bias exists.
Over the last 2 decades, catheter-based treatment of
AD has become the preferred therapy compared with
urgical revascularization. Treatment of VAS has evolved
ore slowly than endovascular therapies in the iliac,
enal, and coronary arteries. A major impediment to
reatment has been a nonpayment decision by Medicare
n 1984. However, since that time there have been
ignificantly more favorable data supporting the safety,
fficacy, and benefit of VAS. Nonpayment for percuta-
eous vertebral artery therapies is difficult to understand
n view of the positive track record for percutaneous
ransluminal angioplasty and stenting in other vascular
erritories and the lack of treatment alternatives for a
isease with a 2-year mortality for medically treated VBS
isease of 30% and a combined surgical morbidity/
ortality of 25%. Therefore, it seems appropriate that
his nonpayment decision be revisited.
tudy limitations. Our data reflect our clinical practice at
he Ochsner Clinic Foundation, including dedicated
igh-volume interventionalists who benefited from the
ooperation and support of a team of neurologists and
euroradiologists, and might not be reproducible under
ess ideal conditions. The major limitation of this study is
ts retrospective nature, which does not allow direct
omparison with other treatment strategies. A minor
imitation is the lack of angiographic core laboratory
nalysis.
onclusions
ur results demonstrate the safety and feasibility of
reating symptomatic vertebral artery stenotic lesions
ith endovascular stent therapy. The excellent safety
esults and durability of symptom-free outcomes support
he efficacy of endovascular stent therapy for symptomatic
AS. Vertebral stenting offers a safer and less morbid
lternative than open surgery and should become the
referred therapy for symptomatic vertebral artery ath-
rosclerotic obstructive disease.
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